First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

Osaka, JAPAN and King of Prussia, Pa., USA • The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is und…

CSL Behring & LaTrobe University partnership

UQ, CEPI and CSL partner for COVID-19

• CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate • …

Development of COVID-19 immunoglobulin commences

Plasma-derived therapeutic with potential to treat serious complications of COVID-19.

CSL Donates to Indonesian Relief Operations

CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunam…

CSL a Top 100 Company for Diversity & Inclusion

Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global Diversity and Inclusion Index

First SCIg Approved for CIDP

HIZENTRA, the First Subcutaneous Immunoglobulin (SCIg) Approved for CIDP

World Haemophilia Day

CSL Behring Marks World Haemophilia Day by Shipping Bleeding Disorders Medicines to the World Federation of Haemophilia